Baird analyst Michael Halloran downgrades Generac Hldgs (NYSE:GNRC) from Outperform to Neutral and lowers the price target from $122 to $119.
BioXcel Earnings Miss Q1 Estimates Due To Higher Costs, Expects Uptick In Revenues
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) reported first-quarter FY23 revenues of $206,000,